Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmetec Plus, is an angiotensin‑1 (AT1) receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is prescribed for adults. GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmetec Plus combines an ARB with a thiazide diuretic to manage high blood pressure through complementary mechanisms.

- Hypertension: lowers systolic and diastolic blood pressure in patients requiring dual therapy. - Heart failure prevention: reduces the risk of cardiovascular events in hypertensive patients with additional risk factors. - Renal protection: helps slow progression of kidney damage associated with long‑term hypertension.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing quickly. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Electrolyte imbalance: low potassium or sodium levels. - Increased urination: due to the diuretic component. - Mild gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: elevated potassium levels, potentially dangerous. - Angioedema: swelling of face, lips, tongue, or throat. - Severe electrolyte disturbances: significant hyponatremia or hypokalemia. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating Olmetec Plus, clinicians should assess patient history and monitor relevant parameters.

- Renal function: evaluate creatinine clearance and adjust if impaired. - Electrolyte levels: check potassium and sodium before and during treatment. - Volume status: ensure patient is not dehydrated or volume‑depleted. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Drug interactions: review concomitant medications for potential additive effects. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmetec Plus may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients can increase risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, risk of hyperkalemia. - Antidiabetic agents: may enhance hypoglycaemic effect, requiring dose adjustment.